Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Vanda Pharmaceuticals Inc. (VNDA) Stock · SELL · CRISIS | LOPJLB

Vanda Pharmaceuticals Inc. (VNDA)

Healthcare · Biotechnology · NASDAQ · US

$4.53-0.66%Close

SELLCRISIS · day 5

VNDA▼ SELL

$4.53-0.66%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $272M
Beta: 0.65
P/E (TTM): -0.98

Short % float: 15.78%
Days to cover: 12.1
SI change: +10.5%

1W: -5.82%
1M: -13.71%

vs SPY 1W: -7.38%
vs SPY 1M: -15.48%

Industry peers

FMP comparable companies · ranked by market cap

ACHVSELLAchieve Life Sciences, Inc.$720MBEARQ -10$7.01-0.69%
ALLOSELLAllogene Therapeutics, Inc.$518MCRISISQ -12$1.50-2.10%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders,…

Employees: 533
Headquarters: US
Founded: 2006
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 60.1M
Float: 89.5%

vandapharma.com ↗

Key executives

Mihael H. Polymeropoulos — Founder, President, Chief Executive Officer & Chairman of The Board

Daniel McGuire — Senior Vice President, General Counsel & Secretary

Joakim Wijkstrom — Senior Vice President & Chief Marketing Officer

SEC filings

EDGAR · CIK 13471780 · VNDA

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish1368.4%

Neutral526.3%

Bearish15.3%

L $10.00Avg $15.50H $21.00

Target$15.50+242.16%

Last$4.53

Company news

defenseworld.net · 4d ago

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC Wainwright

gurufocus.com · 7d ago

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

prnewswire.com · 7d ago

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

prnewswire.com · 10d ago

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

prnewswire.com · 37d ago

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

prnewswire.com · 47d ago

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

gurufocus.com · 48d ago

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

prnewswire.com · 48d ago

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

zacks.com · 59d ago

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

seekingalpha.com · 65d ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

defenseworld.net · 65d ago

Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA

defenseworld.net · 65d ago

Vanda Pharmaceuticals Q2 Earnings Call Highlights

marketbeat.com · 65d ago

Vanda Pharmaceuticals Q2 Earnings Call Highlights

zacks.com · 65d ago

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

prnewswire.com · 65d ago

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

prnewswire.com · 72d ago

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

prnewswire.com · 85d ago

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

prnewswire.com · 86d ago

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

prnewswire.com · 91d ago

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

Market news & ticker search · RSS for VNDA

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE